ArticleFuture oncology (London, England)2025
A clinical model for growth rate-driven prediction of histological subtypes in invasive pulmonary adenocarcinomas.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo develop and validate a nomogram for predicting high - grade components in primary lung adenocarcinomas using tumor growth rate and clinical radiological characteristics. MATERIALS &
methodsThis retrospective study included 735 patients who underwent surgical resection for lung adenocarcinoma. Tumor segmentation was performed on two preoperative CT scans to calculate the specific growth rate (SGR), defined as the natural logarithm of 2 divided by the volume doubling time (VDT) of the tumor. A nomogram was constructed using multivariable logistic regression analysis with significant predictors.
resultsThe nomogram included tumor volume, consolidation - to - tumor ratio (CTR), and SGR. The model showed excellent discrimination in the training cohort (AUC = 0.884), validation cohort (AUC = 0.910), and test cohort (AUC = 0.969). Decision curve analysis indicated a higher net benefit compared to imaging or growth models alone.
conclusionsThe nomogram, incorporating clinical and radiological characteristics with tumor growth metrics, accurately predicted high - grade components in primary lung adenocarcinomas. This tool may aid in preoperative planning and personalized treatment. Future work should focus on prospective multic - center validation and exploring automated segmentation methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.